These findings confirmed the establishment of the NAFLD model, with subsequent findings revealing that ALG9 treatment decreased ALT and AST levels and alleviated HFD-induced liver damage. The gene discussed is ALG9; the disease is metabolic dysfunction-associated steatotic liver disease.